<DOC>
	<DOCNO>NCT01163942</DOCNO>
	<brief_summary>The purpose study examine effect G-CSF disease free survival overall survival aplastic anaemia patient also receive ATG Cyclosporin A .</brief_summary>
	<brief_title>Randomized Study In Severe Aplastic Anemia Patients Receiving Atg , Cyclosporin A , With Or Without G-CSF ( SAA-G-CSF )</brief_title>
	<detailed_description>Open label , randomize , control study G-CSF , ATG Cyclosporin A versus ATG Cyclosporin A . Subjects evaluate hematologic response day 240 . Subjects demonstrate partial complete remission day 120 randomize receive either second course ATG continue current regimen . Subjects demonstrate partial complete remission continue current regimen day 240 maintenance complete remission 30 day . The last day study treatment day 240 .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Severe severe aplastic anemia Less 6 month diagnosis severe aplastic anemia bone marrow biopsy Ethical Before randomization do subject legally acceptable representative must give write informed consent participation study Eligibility HLAmatched sibling donor transplant Prior therapy ATG Cyclosporin A &lt; 4 week enrollment Treatment GCSF &lt; 2 week enrollment Other growth factor &lt; 4 week enrollment Diagnosis Fanconi anemia , dyskeratosis congenita congenital bone marrow failure syndrome Evidence myelodysplastic disease Diagnosis previous history carcinoma ( except local cervical , basal cell , squamous cell , melanoma ) Subjects infection , hepatic , renal cardiac , metabolic concurrent disease severity death imminent Subject pregnant ( e.g . positive HCG test ) breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>